Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Compugen develops discovery platform for protein family members
Compugen said that the analysis of the in silico prediction and selection results for the B7/CD28 protein family, the first of three such families selected for validation activities
Compugen said that the analysis of the in silico prediction and selection results for the B7/CD28 protein family, the first of three such families selected for validation activities
The initiation of the study for S*BIO’s SB1317 or TG02 has triggered a payment from S*BIO’s development and commercialisation partner for the program, Tragara Pharmaceuticals. Earlier, in January
Rexahn Pharma said that the patent covers neurotherapeutic pharmaceutical formulation for cefazoline sulfone, cefazoline sulfoxide, ceftriaxone sulfoxide, and ceftriaxone sulfone for treating neurological disease and behavioral and cognitive
The lead product associated with the arrangement is ARC19499, a synthetic, subcutaneously-administered hemophilia therapy currently in a Phase I clinical trial in the UK. Baxter said that ARC19499
Medgenics has signed a preclinical development and option agreement with the international biopharmaceutical company worth up to $7m in payments that included funding for preclinical development of Medgenics’
ImmunGene’s technology empowers monoclonal antibodies targeted to tumor cells by fusing them to immune effector molecules; that is, cytokine, chemokine and co-stimulatory molecules, thereby combining the specificity of
FDA said that the sildenafil may interact with prescription drugs known as nitrates, including nitroglycerin and can dangerously lower blood pressure. The FDA is investigating the reported death
The UK regulatory agency has approved Bafna for the manufacturing of Finasteride in strength of 5 mg. Finasteride is an antiandrogen which acts by inhibiting 5-alpha reductase, the
ORCA was designed to reflect real world conditions when managing PPR in a large, diverse population of rosacea patients undergoing routine care at 271 community-based medical practices. Galderma
Rockwell’s data from the company’s Phase IIb dose ranging clinical trial demonstrated a 13% dose reduction in ESA and 0.79g/dL increase in hemoglobin compared to placebo in the